Ogsiveo (Nirogacestat Hydrobromide) Patent Expiration, LOE Window & CMS Spending
Ogsiveo (Nirogacestat Hydrobromide) by Springworks Therapeutics: FDA Orange Book core substance LOE 2039-08-09 (last listed 2043-05-19), 0 AB generics, $39.9M 2024 CMS Part D & Medicaid spend, and $29,000 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Springworks Therapeutics |
| FDA Application & Pathway | N217677 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2039-08-09 |
| Last Listed Patent or Exclusivity Date | 2043-05-19 |
| Orange Book Patents (*PED Extensions) | 29 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $39.9M |
| 2024 Medicare Part D Spend | $20.0M |
| 2024 Medicaid Spend | $19.9M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($29,000 intro WAC) |